Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel cancer therapies, today announced it will present updated data from CRDF-004, ...
Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced preclinical data highlighting an ...
Zacks Small Cap Research on MSN
CRDF: Colorectal cancer KOL event
By John Vandermosten, CFA NASDAQ: CRDF Key Opinion Leader Event Places Onvansertib in Context Cardiff Oncology, Inc. (NASDAQ: CRDF) held a key opinion leader (KOL) event on March 25th, 2026, ...
At the recent Gastrointestinal Cancers Symposium hosted by the American Society of Clinical Oncology (ASCO), researchers and doctors shared new find | Cancer ...
Our findings suggest that RAS amplification may confer resistance to anti-EGFR antibodies. Assessing RAS amplification status can help clinicians identify patients who may have a reduced benefit from ...
Researchers at the MRC Laboratory of Medical Sciences (LMS) and Imperial College London have identified an overworked cog in ...
SOUTH SAN FRANCISCO, Calif., Dec. 10, 2025 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway ...
GLP-1 RAs showed a 26% lower risk of CRC compared to aspirin in a large real-world study. Benefits of GLP-1 RAs were consistent across age groups and BMI categories, with semaglutide showing ...
Gemogenovatucel-T Advantage in Clonal Tumor Mutation Burden–High Ovarian Cancer Authors retain all rights in any data supplements associated with their articles. The ideas and opinions expressed in ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results